348 related articles for article (PubMed ID: 35688553)
21. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.
Tan S; Guo X; Bei C; Zhang H; Li D; Zhu X; Tan H
BMC Cancer; 2022 Aug; 22(1):905. PubMed ID: 35986302
[TBL] [Abstract][Full Text] [Related]
22. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-223 attenuates hepatocarcinogenesis by blocking hypoxia-driven angiogenesis and immunosuppression.
Fu Y; Mackowiak B; Feng D; Lu H; Guan Y; Lehner T; Pan H; Wang XW; He Y; Gao B
Gut; 2023 Oct; 72(10):1942-1958. PubMed ID: 36593103
[TBL] [Abstract][Full Text] [Related]
24. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
25. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma.
Wang BJ; Bao JJ; Wang JZ; Wang Y; Jiang M; Xing MY; Zhang WG; Qi JY; Roggendorf M; Lu MJ; Yang DL
World J Gastroenterol; 2011 Jul; 17(28):3322-9. PubMed ID: 21876620
[TBL] [Abstract][Full Text] [Related]
26. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway.
Ma H; Kang Z; Foo TK; Shen Z; Xia B
Hepatology; 2023 Jan; 77(1):33-47. PubMed ID: 35006619
[TBL] [Abstract][Full Text] [Related]
27. CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma.
Zhang R; Wang J; Du Y; Yu Z; Wang Y; Jiang Y; Wu Y; Le T; Li Z; Zhang G; Lv L; Ma H
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007240
[TBL] [Abstract][Full Text] [Related]
28. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
[TBL] [Abstract][Full Text] [Related]
29. Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells.
Cho S; Kim W; Yoo D; Han Y; Hwang H; Kim S; Kim J; Park S; Park Y; Jo H; Pyun JC; Lee M
Sci Rep; 2024 Jan; 14(1):1751. PubMed ID: 38243049
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma.
Gao Y; Xu Q; Li X; Guo Y; Zhang B; Jin Y; Zhu C; Shen Y; Yang P; Shi Y; Jin R; Liu D; Ouyang Y; Liu X; Wang W; Chen D; Yang T
Cell Death Dis; 2022 Mar; 13(3):213. PubMed ID: 35256589
[TBL] [Abstract][Full Text] [Related]
31. Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma.
Song M; Wang L; Jiang S; Liang J; Li W; Rao W; Du Q; Liu G; Meng H; Tang L; Li Z; Yang Y; Zhang L; Zhang B
Int Immunopharmacol; 2024 Mar; 129():111601. PubMed ID: 38350354
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
[TBL] [Abstract][Full Text] [Related]
33. Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling.
Li Z; Gao WQ; Wang P; Wang TQ; Xu WC; Zhu XY; Liu H
Curr Cancer Drug Targets; 2020; 20(11):868-874. PubMed ID: 32748749
[TBL] [Abstract][Full Text] [Related]
34. Intrahepatic inflammatory IgA
Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
[TBL] [Abstract][Full Text] [Related]
35. Fibrotic immune microenvironment remodeling mediates superior anti-tumor efficacy of a nano-PD-L1 trap in hepatocellular carcinoma.
Liu X; Zhou J; Wu H; Chen S; Zhang L; Tang W; Duan L; Wang Y; McCabe E; Hu M; Yu Z; Liu H; Choi CHJ; Sung JJ; Huang L; Liu R; Cheng AS
Mol Ther; 2023 Jan; 31(1):119-133. PubMed ID: 36146933
[TBL] [Abstract][Full Text] [Related]
36. Acesulfame potassium upregulates PD-L1 in HCC cells by attenuating autophagic degradation.
Kim DH; Kwon EJ; Park KG; Jin J; Byun JK
Biochem Biophys Res Commun; 2024 Jun; 711():149921. PubMed ID: 38603831
[TBL] [Abstract][Full Text] [Related]
37. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.
Chui NN; Cheu JW; Yuen VW; Chiu DK; Goh CC; Lee D; Zhang MS; Ng IO; Wong CC
Hepatol Commun; 2022 Jan; 6(1):178-193. PubMed ID: 34558800
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs.
Li Z; Bu J; Zhu X; Zhou H; Ren K; Chu PK; Li L; Hu X; Ding X
Biomater Adv; 2022 May; 136():212761. PubMed ID: 35929305
[TBL] [Abstract][Full Text] [Related]
40. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
